Lupin’s US subsidiary -- Lupin Pharmaceuticals has launched its Donepezil Hydrochloride Tablets, 23 mg having received approval from the United States Food and Drug Administration (FDA) earlier to market a generic equivalent of Eisai Inc's Aricept Tablets, 23mg. Lupin's Donepezil Hydrochloride Tablets, 23 mg are the AB rated generic equivalent of Eisai Inc's Aricept Tablets, 23mg. It is indicated for the treatment of dementia of the Alzheimer's type. Aricept had US sales of $47.1 million (IMS MAT December 2015).
Lupin is an innovation led transnational pharmaceutical company producing and developing a wide range of branded & generic formulations, biotechnology products and APIs globally. The Company is a significant player in the Cardiovascular, Diabetology, Asthma, Pediatric, CNS, GI, Anti-Infective and NSAID space and holds global leadership positions in the Anti-TB and Cephalosporin segment.
